AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

IRB/UVA Tracking #
16462
Contact First Name

Candace K Hudspeth

Contact Email
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
William C. Petersen
Status
OPEN TO ACCRUAL